# Hepatic Arterial Infusion (HAI) With Floxuridine (FUDR) and Dexamethasone (Dex) Combined With Systemic Gemcitabine and Oxaliplatin in Patients With Unresectable Intrahepatic Cholangiocarcinoma (ICC)

> **NCT01862315** · PHASE2 · COMPLETED · sponsor: **Memorial Sloan Kettering Cancer Center** · enrollment: 55 (actual)

## Conditions studied

- Intrahepatic Cholangiocarcinoma
- Peripheral Cholangiocarcinoma
- Cholangiolar Carcinoma
- Cholangiocellular Carcinoma

## Interventions

- **DRUG:** Floxuridine (FUDR)
- **DRUG:** dexamethasone
- **DRUG:** Gemcitabine
- **DRUG:** Oxaliplatin
- **OTHER:** MRI
- **OTHER:** Research blood draws

## Key facts

- **NCT ID:** NCT01862315
- **Lead sponsor:** Memorial Sloan Kettering Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-05
- **Primary completion:** 2025-03-18
- **Final completion:** 2025-03-18
- **Target enrollment:** 55 (ACTUAL)
- **Last updated:** 2025-03-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01862315

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01862315, "Hepatic Arterial Infusion (HAI) With Floxuridine (FUDR) and Dexamethasone (Dex) Combined With Systemic Gemcitabine and Oxaliplatin in Patients With Unresectable Intrahepatic Cholangiocarcinoma (ICC)". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT01862315. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*